The plaintiff argues that the omitted information is imperative to the stockholders ability to vote on the proposed merger between Tyme and Syros. Particularly, the complaint states that the proxy statement omits and misrepresents financial projections for Tyme, Syros and combined company, the background of the proposed transaction and any potential conflicts of interest with the financial advisor to the transaction. However, the plaintiff argues that the Proxy Statement omits and misrepresents material information necessary for stockholders to make a decision about the merger. The complaint further states that on August 9, 2022, Tyme’s corporate directors approved and filed a SEC required Definitive Proxy Statement which recommends that Tyme stockholders vote in favor of the merger. The plaintiff purports that under Nasdaq listing rules, Tyme would have to obtain stockholder approval for such stock issuance, therefore making the merger contingent on such approval. Under the merger agreement, Tyme would issue shares of its Class C common stock increasing its outstanding stock by 94%. The complaint states that on July 3, 2022, Tyme entered into an agreement and plan of merger with Syros in which the two companies would combine with Tyme stockholders receiving 0.4312 shares of Syros common stock for each share of Tyme common stock. Further, Richard Lawrence is and has been an owner of Tyme common stock at all times relevant to the complaint. and its corporate directors alleging securities violations in connection with an attempted merger with Syros Pharmaceuticals, Inc.Īccording to the complaint, Tyme is a Delaware corporation traded on the Nasdaq and a biotechnology company focused on developing cancer metabolism-based therapies. On Tuesday, Richard Lawrence filed a complaint in the District of Delaware against Tyme Technologies, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |